| Form type | Sec Links | Description | Filing date | Reporting date |
|---|
Form type | Sec Links | Description | Filing date | Reporting date |
|---|---|---|---|---|
| 6-K | Report | POSITIVE CHMP OPINION ON BLENREP IN EU | May 23, 2025 | May 23, 2025 |
| 6-K | Report | FDA APPROVES NUCALA COPD INDICATION | May 23, 2025 | May 23, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | May 23, 2025 | May 23, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | May 22, 2025 | May 22, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | May 21, 2025 | May 21, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | May 20, 2025 | May 20, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | May 20, 2025 | May 20, 2025 |
| 6-K | Report | BLENREP FOR 2L+ MULTIPLE MYELOMA APPROVED IN JAPAN | May 19, 2025 | May 19, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | May 19, 2025 | May 19, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | May 16, 2025 | May 16, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | May 15, 2025 | May 15, 2025 |
| 6-K | Report | GSK TO ACQUIRE EFIMOSFERMIN | May 14, 2025 | May 14, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | May 14, 2025 | May 14, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | May 13, 2025 | May 13, 2025 |
| 6-K | Report | UPDATE ON BELRESTOTUG DEVELOPMENT PROGRAMME | May 13, 2025 | May 13, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | May 13, 2025 | May 13, 2025 |
| 6-K | Report | BLOCK LISTING INTERIM REVIEW | May 12, 2025 | May 12, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | May 12, 2025 | May 12, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | May 9, 2025 | May 9, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | May 8, 2025 | May 8, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | May 8, 2025 | May 8, 2025 |
| 6-K | Report | LINERIXIBAT GLISTEN PIII TRIAL DATA AT EASL | May 8, 2025 | May 8, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | May 8, 2025 | May 8, 2025 |
| 6-K | Report | RESULT OF AGM | May 7, 2025 | May 7, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | May 7, 2025 | May 7, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | May 6, 2025 | May 6, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | May 2, 2025 | May 2, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | May 1, 2025 | May 1, 2025 |
| 6-K | Report | TOTAL VOTING RIGHTS | May 1, 2025 | May 1, 2025 |
| 6-K | Report | NUCALA MATINEE DATA IN COPD PUBLISHED IN NEJM | May 1, 2025 | May 1, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | May 1, 2025 | May 1, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | Apr 30, 2025 | Apr 30, 2025 |
| 6-K | Report | 1ST QUARTER RESULTS | Apr 30, 2025 | Apr 30, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | Apr 29, 2025 | Apr 29, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | Apr 28, 2025 | Apr 28, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | Apr 25, 2025 | Apr 25, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | Apr 24, 2025 | Apr 24, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | Apr 23, 2025 | Apr 23, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | Apr 22, 2025 | Apr 22, 2025 |
| 6-K | Report | BLENREP LICENSED BY UK MHRA | Apr 17, 2025 | Apr 17, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | Apr 17, 2025 | Apr 17, 2025 |
| 6-K | Report | AREXVY NOW ACIP RECOMMENDED FOR 50-59 AT RIS | Apr 17, 2025 | Apr 17, 2025 |
| 6-K | Report | GSK 5-IN-1 MENINGITIS VACCINE RECOMMENDED IN US | Apr 17, 2025 | Apr 17, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | Apr 17, 2025 | Apr 17, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | Apr 16, 2025 | Apr 16, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | Apr 15, 2025 | Apr 15, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | Apr 15, 2025 | Apr 15, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | Apr 14, 2025 | Apr 14, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | Apr 14, 2025 | Apr 14, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | Apr 11, 2025 | Apr 11, 2025 |